Drug Trial Radar · NCT07578467
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Jan 31, 2027
Primary completion
May 31, 2030
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Abramson Cancer Center at Penn MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aprea Therapeutics
- First posted
- May 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat early-stage throat cancer that is caused by HPV. The goal of this study is to treat cancer effectively while reducing side effects and helping patients maintain a better quality of life over the long term. Researchers hope that this approach will be just as successful-or possibly more successful-than current treatments, which already have high cure rates. Participants will: * Take 800mg of ATRN-119 every day for 10 days * Receive 1 treatment (called a "fraction") of SBRT to the neck on day 3 of ATRN-119 dosing. * Keep a short diary to track ATRN-119 dosing. The diary will be provided by study team * Receive standard of care treatment after treatment with ATRN-119 + SBRT including TransOral Robotic Surgery (TORS) to remove the primary tumor with Neck Dissection and adjuvant therapy (if indicated) * Receive additional safety checkups and tests by researchers during routine visits with their cancer doctor for 2 years after study treatment
Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- HPV (Human Papillomavirus)-Associated Carcinoma
- HPV Associated Cancers
- Oropharyngeal HPV Squamous Cell Carcinoma
Interventions
ATRN-119Drug
ATRN-119 at 800 mg QD (every day) for 10 days
Stereotactic Body Radiation Therapy (SBRT)Radiation
10 Gy administered to nodal disease (neck) only on day 3 of ATRN-119 dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Feasibility of a neo-adjuvant approach combining ATRN with SBRT before TORSTime frame: Within 6 weeks after study treatment
- Phase II: Major pathologic response (MPR) rate of radiated nodal diseaseTime frame: Immediately after standard of care primary tumor removal surgery
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.